Search results for "Angiotensin"

showing 10 items of 396 documents

Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot study

2018

Background: Impaired exercise capacity is the most disabling symptom in patients with heart failure with reduced ejection fraction (HFrEF). Despite sacubitril/valsartan showing reduced long-term morbidity and mortality over enalapril in HFrEF, its effects on short-term functional capacity remain uncertain. We sought to evaluate the effects of sacubilril/valsartan on a 30-day six-minute walk test in eligible patients with HFrEF. Methods and results: From November 1, 2016 to February 1, 2017, a total of 58 stable symptomatic patients with HFrEF were eligible for sacubitril/valsartan and underwent 6-MWT before and 30 days after initiation of sacubitril/valsartan therapy. A mixed-effects model …

Malemedicine.medical_specialtyTime FactorsTetrazolesPilot ProjectsWalk Test030204 cardiovascular system & hematologySacubitrilCohort Studies03 medical and health sciencesAngiotensin Receptor AntagonistsElectrocardiography0302 clinical medicineInternal medicineExercise capacityMedicineHumans6-minute walk test030212 general & internal medicineEnalaprilProspective StudiesSacubitril/valsartanAgedAged 80 and overEjection fractionExercise Tolerancebusiness.industryAminobutyratesBiphenyl CompoundsExercise capacityMiddle Agedmedicine.diseaseHeart failure with reduced ejection fractionDrug CombinationsTreatment OutcomeValsartanHeart failureCardiologyValsartanFemaleCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drug
researchProduct

Effects of a nitrate-free interval on tolerance, vasoconstrictor sensitivity and vascular superoxide production

2000

Abstract OBJECTIVES In the present study, we tested whether a nitrate-free interval is able to prevent increases in vascular superoxide (O2•−) and the development of hypersensitivity to vasoconstrictors and whether this may result in restoration of vascular nitroglycerin (NTG) sensitivity. BACKGROUND Intermittent NTG-patch treatment (12 h patch on/patch off) has been shown to increase ischemic periods in patients with stable coronary arteries, suggesting a rebound-like situation during the patch-off period. Recently, we demonstrated that long-term treatment with NTG induces tolerance, which was in part related to increases in vascular O2•− and increased vasoconstrictor sensitivity. METHODS …

Malemedicine.medical_specialtyTime Factorsgenetic structuresVasodilator AgentsBlotting WesternVasodilationIn Vitro TechniquesSuperoxide dismutaseNitroglycerinchemistry.chemical_compoundDrug toleranceInternal medicinemedicineAnimalsEndothelial dysfunctionPhenylephrinebiologySuperoxide DismutaseSuperoxidebusiness.industryDrug Tolerancemedicine.diseaseAngiotensin IIAcetylcholineeye diseasesOxidative StressEndocrinologychemistryVasoconstrictionbiology.proteinFemaleEndothelium VascularRabbitsmedicine.symptombusinessCardiology and Cardiovascular MedicineVasoconstrictionmedicine.drugJournal of the American College of Cardiology
researchProduct

Early Sacubitril/Valsartan-driven Benefit on Exercise Capacity in Heart Failure With Reduced Ejection Fraction: A Pilot Study

2017

Malemedicine.medical_specialtyTreatment outcomeTetrazolesPilot Projects030204 cardiovascular system & hematology030226 pharmacology & pharmacyAngiotensin Receptor Antagonists03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansNeprilysinAgedHeart FailureExercise ToleranceEjection fractionbusiness.industryAminobutyratesBiphenyl CompoundsStroke VolumeGeneral MedicineExercise capacitymedicine.diseaseDrug CombinationsTreatment OutcomeHeart failureCardiologyValsartanFemaleNeprilysinbusinessSacubitril ValsartanRevista Española de Cardiología (English Edition)
researchProduct

The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP.

2012

Blockade of the renin-angiotensin-aldosterone system (RAAS) affects both the glomerulus and tubules. We aimed to investigate the effect of irbesartan on the tubular markers: urinary (u) neutrophil gelatinase associated protein (NGAL), Kidney injury molecule 1 (KIM1) and liver-fatty acid-binding protein (LFABP).A substudy of a double-masked, randomized, cross-over study including 52 patients with type 2 diabetes, hypertension and microalbuminuria. After 2 months washout of all antihypertensive medication except bendroflumethiazid, patients were treated in random order with irbesartan 300, 600 and 900 mg for 2 months.Urinary tubular markers at baseline and after each treatment period (ELISA),…

Malemedicine.medical_specialtyUrinary systemClinical BiochemistryUrologyRenal functionEnzyme-Linked Immunosorbent AssayType 2 diabetesurologic and male genital diseasesFatty Acid-Binding ProteinsDiabetic nephropathyRenin-Angiotensin SystemIrbesartanLipocalin-2Internal medicineDiabetes mellitusProto-Oncogene ProteinsmedicineHumansDiabetic NephropathiesHepatitis A Virus Cellular Receptor 1AgedMembrane Glycoproteinsurogenital systembusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseLipocalinsEndocrinologyKidney TubulesAlbuminuriaReceptors VirusMicroalbuminuriaFemalemedicine.symptombusinessmedicine.drugAcute-Phase ProteinsScandinavian journal of clinical and laboratory investigation
researchProduct

Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study

2020

Altres ajuts: Conselleria d'Educació, Investigació, Cultura i Esport GV/2018/116 Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low-density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ventricle remodelling and heart failure-related complications. The aim of this study was to assess the relationship between circulating PCSK9 and 6 month cardiac magnetic resonance imaging-derived left ventricular ejection fraction (LVEF) after a first ST-segment elevation myocardial infarction (STEMI). We prospectively evaluated 40…

Malemedicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemLeft ventricular ejection fractionCardiac magnetic resonancemedicine.medical_treatmentMyocardial InfarctionInfarctionAngiotensin-Converting Enzyme InhibitorsPilot Projects030204 cardiovascular system & hematologyVentricular Function LeftPCSK9Angiotensin Receptor Antagonists03 medical and health sciences0302 clinical medicineCardiac magnetic resonance imagingOriginal Research ArticlesInternal medicinemedicineST‐segment elevation myocardial infarctionHumansST segmentOriginal Research Article030212 general & internal medicineMyocardial infarctioncardiovascular diseasesAgedKillip classEjection fractionmedicine.diagnostic_testbusiness.industryPercutaneous coronary interventionStroke VolumeMiddle Agedmedicine.diseaseST-segment elevation myocardial infarctionlcsh:RC666-701Heart failureCardiologyST Elevation Myocardial InfarctionProprotein Convertase 9Cardiology and Cardiovascular Medicinebusiness
researchProduct

Long-Term Structural and Functional Myocardial Adaptations in Healthy Living Kidney Donors: A Pilot Study

2015

Background and Aims Compensatory renal hypertrophy following unilateral nephrectomy (UNX) occurs in the remaining kidney. However, the long-Term cardiac adaptive process to UNX remains poorly defined in humans. Our goal was to characterize myocardial structure and function in living kidney donors (LKDs), approximately 12 years after UNX. Methods and Results Cardiac function and structure in 15 Italian LKDs, at least 5 years after UNX (median time from donation = 8.4 years) was investigated and compared to those of age and sex matched U.S. citizens healthy controls (n = 15). Standard and speckle tracking echocardiography (STE) was performed in both LKDs and controls. Plasma angiotensin II, a…

Malemedicine.medical_specialtylcsh:MedicinePilot Projectschemistry.chemical_compoundInternal medicineNatriuretic Peptide BrainLiving DonorsmedicineHumanslcsh:ScienceAldosteroneKidney transplantationAgedKidneyMultidisciplinaryAldosteronebusiness.industryAngiotensin IIMyocardiumlcsh:RMyocardial adaptations Kidney donorsCompensatory renal hypertrophyHeartMiddle AgedUnilateral nephrectomymedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareKidney TransplantationAngiotensin IIPeptide FragmentsStructure and functionCardiovascular physiologyCross-Sectional Studiesmedicine.anatomical_structureEndocrinologychemistryCardiologylcsh:QFemalebusinessSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotorieAtrial Natriuretic FactorProcollagenResearch ArticlePLOS ONE
researchProduct

Effectiveness and Tolerability of Fixed-Dose Combination Enalapril plus Nitrendipine in Hypertensive Patients Results of the 3-Month Observational, P…

2009

Background and objective: Monotherapy with any class of antihypertensive drug effectively controls blood pressure (BP) in only about 50% of patients. Consequently, the majority of patients with hypertension require combined therapy with two or more medications. This study aimed to evaluate the effectiveness (systolic BP [SBP]/diastolic BP [DBP] control) and tolerability of the fixed-dose combination enalapril/nitrendipine 10 mg/20 mg administered as a single daily dose in hypertensive patients. Methods: This was a post-authorization, multicentre, prospective, observational study conducted in primary care with a 3-month follow-up. Patients throughout Spain with uncontrolled hypertension (>= …

Malemedicine.medical_specialtymedicine.drug_classSystolic hypertensionFixed-dose combinationPopulationAngiotensin-Converting Enzyme InhibitorsBlood PressureEssential hypertensionEnalaprilInternal medicinemedicineProduct Surveillance PostmarketingHumansPharmacology (medical)EnalaprilProspective StudieseducationAntihypertensive drugAntihypertensive Agentseducation.field_of_studyDose-Response Relationship DrugPrimary Health Carebusiness.industryNitrendipineGeneral MedicineMiddle Agedmedicine.diseaseCalcium Channel BlockersDrug CombinationsBlood pressureTolerabilityAnesthesiaHypertensionFemalebusinessmedicine.drug
researchProduct

Antihypertensive effects of lactoferrin hydrolyzates: Inhibition of angiotensin- and endothelin-converting enzymes

2013

The potential of bovine lactoferrin (LF) as a source of antihypertensive peptides acting on the renin-angiotensin system (RAS) and the endothelin (ET) system as dual vasopeptidase inhibitors has been examined. For this purpose enzymatic LF hydrolyzates (LFHs) were generated by trypsin and proteinase K digestions. Permeate fractions with molecular masses lower than 3 kDa (LFH <3 kDa) were orally administered to spontaneously hypertensive rats (SHRs). Although both LFHs <3 kDa showed in vitro angiotensin I-converting enzyme (ACE)-inhibitory activity, only proteinase K LFH <3 kDa exerted an in vivo antihypertensive effect. The proteinase K LFH <3 kDa and a previously characterized pepsin LFH <…

Malemedicine.medical_treatmentLactoferrin hydrolyzatesMolecular Sequence DataPeptideAngiotensin-Converting Enzyme InhibitorsBlood PressureIn Vitro TechniquesPeptidyl-Dipeptidase AECE-dependent vasoconstrictionAnalytical ChemistryIn vivoRats Inbred SHRmedicineVasopeptidase InhibitorsAnimalsAmino Acid SequenceAntihypertensive Agentschemistry.chemical_classificationProteasebiologyLactoferrinEndothelinsHydrolysisGeneral MedicineVasopeptidase inhibitorsRenin–angiotensin systemProteinase KTrypsinEndothelin systemRatsLactoferrinEnzymeCarotid ArteriesBiochemistrychemistryVasoconstrictionHypertensionbiology.proteinCattleRabbitsFood Sciencemedicine.drugACE-dependent vasoconstriction
researchProduct

Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats.

2006

Nebivolol is a β 1 -receptor antagonist with vasodilator and antioxidant properties. Because the vascular NADPH oxidase is an important superoxide source, we studied the effect of nebivolol on endothelial function and NADPH oxidase activity and expression in the well-characterized model of angiotensin II–induced hypertension. Angiotensin II infusion (1 mg/kg per day for 7 days) caused endothelial dysfunction in male Wistar rats and increased vascular superoxide as detected by lucigenin-derived chemiluminescence, as well as dihydroethidine staining. Vascular NADPH oxidase activity, as well as expression at the mRNA and protein level, were markedly upregulated, as well as NOS III uncoupled, …

Malerac1 GTP-Binding Proteinmedicine.medical_specialtyLuminescenceEndotheliumNitric Oxide Synthase Type IIIAdrenergic beta-AntagonistsNitric OxideFluorescenceCell LineNebivololchemistry.chemical_compoundHemoglobinsSuperoxidesInternal medicineInternal MedicinemedicineAnimalsHumansBenzopyransRats WistarCyclic GMPNitritesOxidase testNADPH oxidaseLuminescent AgentsbiologyChemistrySuperoxideAngiotensin IIMyocardiumNADPH OxidasesDicarbethoxydihydrocollidinePhosphoproteinsAngiotensin IINebivololRatsNitric oxide synthasemedicine.anatomical_structureEndocrinologyEthanolaminesNOX1biology.proteinAcridinesBlood VesselsLuminolEndothelium Vascularmedicine.drugSignal TransductionHypertension (Dallas, Tex. : 1979)
researchProduct

Role of continuous moisture profile monitoring by inline NIR spectroscopy during fluid bed granulation of an Enalapril formulation

2010

Granulation and tableting are closely related process steps in the supply chain of pharmaceutical products. Even today, these steps are still optimized independently by trial and error. On the framework of a process analytical technology approach, these processes were evaluated in an integrated approach. Enalapril maleate is a low-dose drug substance with poor granulating and tableting behavior. In order to verify how granulation influences tableting properties, different granulation experiments were performed.Granulation experiments with fast spraying rate and fast drying as well as fast spraying rate and slow drying, and also combinations of both were run. The obtained granules were then …

Materials scienceDrug CompoundingProcess analytical technologyPharmaceutical ScienceAngiotensin-Converting Enzyme InhibitorsIndentation hardnessQuality by DesignPlacebosGranulationTabletingEnalaprilHardnessDrug DiscoveryDesiccationParticle SizeProcess engineeringFluid Bed GranulationPharmacologySpectroscopy Near-InfraredMoisturebusiness.industryOrganic ChemistryNear-infrared spectroscopyWaterbusinessTabletsDrug Development and Industrial Pharmacy
researchProduct